Prasugrel: Reassessing Its Role in Contemporary Antiplatelet Therapy.

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Managing acute coronary syndrome (ACS) and atherosclerotic cardiovascular disease (ASCVD) involves balancing ischemic protection and bleeding risk.
• Dual antiplatelet therapy (DAPT) is crucial, with aspirin as a cornerstone, but selecting the second agent is complex.
• Clopidogrel, a P2Y12 inhibitor, shows variable response due to CYP2C19 polymorphisms, prompting development of more potent agents like prasugrel and ticagrelor.

Purpose of the Study:

• To reexamine the role of prasugrel in antiplatelet therapy.
• To focus on evidence supporting dose optimization and patient selection for prasugrel.
• To consider population-specific factors influencing prasugrel efficacy and safety.

Main Methods:

• Review of contemporary evidence on prasugrel use.
• Analysis of studies focusing on dose optimization strategies.
• Evaluation of patient selection criteria for prasugrel.
• Consideration of population-specific data, particularly in Asian populations.

Main Results:

• Potent P2Y12 inhibitors like prasugrel provide faster and more consistent platelet inhibition than clopidogrel.
• A "one-size-fits-all" approach to prasugrel dosing may increase bleeding risk, offsetting ischemic benefits.
• Evidence supports tailoring prasugrel therapy based on individual ischemic and bleeding risks.

Conclusions:

• Prasugrel is a valuable antiplatelet option when individualized.
• Dose optimization and careful patient selection are key to maximizing prasugrel's benefit-risk profile.
• Prasugrel is particularly relevant for patients undergoing complex percutaneous coronary intervention and selected Asian populations.